Stenotrophomonas maltophilia is emerging as an important cause of disease in nosocomial 23 and community-acquired settings, including bloodstream, wound and catheter-associated 24 infections. Cystic fibrosis airways also provide optimal growth conditions for various 25 opportunistic pathogens with high antibiotic tolerance, including S. maltophilia. Currently, 26 there is no rapid, cost-effective, and accurate molecular method for detecting this potentially 27 life-threatening pathogen, particularly in polymicrobial specimens, suggesting that its true 28 prevalence may be underestimated. Here, we used large-scale comparative genomics to 29 identify a specific genetic target for S. maltophilia, with subsequent development and 30 validation of a real-time PCR assay for its detection. Analysis of 165 Stenotrophomonas spp.
Introduction
S. maltophilia-specific genetic target, sequence alignments were used to locate conserved 138 regions. Although some variation was allowed within the amplicon, primer-and probe-139 binding regions required 100% sequence identity in all S. maltophilia strains to avoid false 140 negatives. Oligo self-dimers and heterodimers were assessed in silico using NetPrimer derived isolates cultured from individuals with CF identified either by amplified rRNA gene 155 restriction analysis (n=8 (28)) or in silico multilocus sequence typing (n=8 (29) (Table S1 ). Following identification of the species boundary for S. maltophilia, we next identified loci 210 specific for S. maltophilia. A single 4kb region was found to be S. maltophilia-specific, being 211 present in the 134 S. maltophilia genomes but absent or highly divergent in the other 212 Stenotrophomonas spp., including S. indicatrix and S. lactitubi. The genetic coordinates for 213 these loci are 3,935,000-3,939,000 in S. maltophilia K279a, spanning gene-coding regions for 214 formate dehydrogenase (α, β, and γ-subunits; encoded by fdnG, fdnH, and fdnI, respectively).
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Upon identification of a suitable 344 bp S. maltophilia-specific amplicon, a microbial 216 discontiguous MegaBLAST analysis was conducted to confirm specificity (performed There was an 84.6% congruence between the two methods, with two PCR-positive sputa 250 (SCHI0020 Day 1 and SCHI0021 Day 1) being negative by culture (Table 1) 
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There is currently a lack of a rapid, cost-effective, accessible, and accurate diagnostic method 280 for S. maltophilia detection, particularly from polymicrobial clinical specimens such as CF 281 sputa. As S. maltophilia is thought to be the only Stenotrophomonas species to cause human 282 disease, mass spectrometry-based systems such as VITEK 2 and VITEK MS are a common 283 diagnostic method in large, centralized pathology laboratories. However, the accuracy of 284 species determination using mass spectrometry is heavily dependent on the quality of the 285 associated databases, and it is currently unknown whether other Stenotrophomonas spp. can 286 be accurately differentiated from S. maltophilia on these systems. In addition, access to this 287 instrument is limited to well-resourced laboratories owing to a large barrier-to-entry cost 288 (~USD$200,000) (34-36). From a genotyping standpoint, 16S rDNA PCR has been used to 289 identify S. maltophilia in blood samples for patients undergoing chemotherapy for leukemia 290 (37), and a multiplex PCR to detect P. aeruginosa, S. maltophilia and B. cepacia successfully 291 identified S. maltophilia in 85% of cases (38). However, these assays have either not been 292 optimized to avoid non-specific amplification in other Stenotrophomonas spp. and members 293 of the closely related Xanthomonas genus, or they require downstream processing (e.g. gel 294 electrophoresis, Sanger sequencing) to confirm results, which is laborious, time-consuming, 295 and raises potential laboratory contamination issues. 296 Therefore, the purpose of this study was to use large-scale comparative genomics to identify 297 a S. maltophilia-specific genetic target, and to subsequently design a highly-specific and 298 accurate real-time PCR-based assay for identifying S. maltophilia. Using this approach, we 299 identified a genetic region specific to S. maltophilia, which was subsequently targeted for 300 assay development. We found that our newly developed assay correctly identified 89 S. 301 maltophilia isolates with 100% accuracy. The accuracy and specificity of this assay is both 302 highly sensitive and selective for S. maltophilia, with an LoQ and LoD of ~94 and ~9 GEs, analysis showed that there were two SNPs in the probe-binding region, including a SNP at 320 the 5' ultimate base of the BHQ probe, which would likely result in poor or no amplification.
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Taken together, we show that our assay is highly specific for S. maltophilia, particularly in 322 clinical samples, but it also has applicability for testing environmental samples, such as 323 hospital water supplies.
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Although the quality of life and life expectancy for people with CF has markedly increased in 325 recent decades due to improvements in antibiotic treatments and clinical management, 326 persistent polymicrobial infections in CF airways remain the primary cause of morbidity and 327 mortality (39). A recent longitudinal study of a single CF patient's airways using a cutting-328 edge metatranscriptomic approach, which measures only the 'active' microbial population 329 through messenger RNA characterisation, revealed that S. maltophilia was the second most 330 prevalent bacterium behind P. aeruginosa in the six months prior to death (39). Our results 331 also revealed a high prevalence of S. maltophilia in adult CF sputa, with 10/16 samples 332 positive for this bacterium according to our assay. As these sputa samples had concurrent 333 culture results, we demonstrated 84.6% congruence to real-time PCR results, with two culture 334 negative samples returning as positive by real-time PCR (SCHI0020 Day 1 and SCHI0021 335 Day 1). This finding demonstrates that our assay has a higher sensitivity for detecting S. 336 maltophilia in CF clinical specimens than culture methods. Of four longitudinally collected 337 sputa, one patient (SCHI0019) had S. maltophilia at all time points (Days 1, 11, and 46; Table   338 1) despite intravenous antibiotic therapy during this time, and another patient, SCHI0002, 339 was positive for S. maltophilia in samples that were collected nearly 12 months apart (Days 1 340 and 320), indicating either long-term airway persistence or reinfection with this organism. In 341 one sputum sample from SCHI0019 (Day 11), the ∆CT value between the 16S rDNA and S. 342 maltophilia PCRs was identical to that of pure S. maltophilia culture ( In conclusion, the ability to accurately, rapidly, and cheaply detect S. maltophilia is critical 356 for understanding the prevalence of this underappreciated opportunistic pathogen and for 357 reducing its burden of disease. The implementation of this assay in the clinical setting will 358 enable researchers, clinicians and pathologists to more accurately identify this multidrug-359 resistant bacterium, particularly in isolates that have been ruled out as other multidrug-360 resistant Gram-negative pathogens, such as P. aeruginosa or Burkholderia spp. Finally, the 361 correct and rapid identification of S. maltophilia will improve antibiotic stewardship 362 measures by enabling more targeted eradication of this pathogen, and in polymicrobial 363 infections such as those commonly found in CF airways, S. maltophilia eradication may 364 reduce the prevalence and persistence of more serious pathogens such as P. aeruginosa, 365 leading to improved quality of life and lifespans for people with CF. 
